Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer

Mayo Clinic Proceedings

Volumn 72, Issue 10, 1997, Pages 932-934

  Wehbe, Tarek W ^a   Stein, Barry S ^b   Akerley, Wallace L ^a  

^a Department of Medical Oncology ^*  (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE PHOSPHATE; MEGESTROL ACETATE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE SULFATE;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; HUMAN; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 0030808736     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.10.932     Document Type: Article

References (18)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. ÇA Cancer J Clin 1996;46:5-27
2. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991;324:236-245
3. Geller J, Albert J, Yen SS. Treatment of advanced cancer of the prostate with megestrol acetate. Urology 1978; 12:537541
4. Geller J, Albert J, Geller S, Lopez D, Cantor T, Yen S. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. J Clin Endocrinol Metab 1976;43:1000-1008
5. Pavone-Macaluso M, De Pauw M, Sucui S, Sylvester R, de Voogt H, Lardennois B, et al. Medroxyprogesterone acetate, diethylstilboestrol and cyproterone acetate in the treatment of prostatic cancer: interim report of a prospective study of the European Organization for Research on the Treatment of Cancer (EORTC) Genito-urinary Tract Cooperative Group. Excerpta Medica International Congress Series No. 611, 1982. pp 436-444
6. Bonomi P, Pessis D, Bunting N, Block M, Anderson K, Wolter J, et al. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol 1985; 12(Suppl l):36-39
7. Daniel F, MacLeod PM, Tyrrell CJ. Megestrol acetate in relapsed carcinoma of prostate. Br J Urol 1990; 65:275277
8. Dawson NA, Conaway M, Winer EP, Lake D, Small EJ, Cooper MR, et al. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a cancer and leukemia group B study [abstractJ. Program Proc Am Soc Clin Oncol 1995; 14:236
9. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150:908-913
10. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;! 1:1566-1572
11. Small EJ, Caroll PR. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-410
12. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. JUrol 1993; 149:607-609
13. Sartor O, Cooper M, Weinberger M, Headlee D, Tompkins A, Thibault A, et al. Flutamide withdrawal, when combined with aminoglutethimide (AG) and hydrocortisone (HC), is surprisingly active in hormone-refractory prostate cancer [abstractJ. Program Proc Am Soc Clin Oncol 1993;12:234
14. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. JUrol 1995; 153:19461947
15. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398
16. Veldscholte J, Ris-Stalpers C, Kuiper G, Jenster G, Berrevoets C, Claasen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990;173:534540
17. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:15411550
18. Colombel M, Olsson CA, Ng PY, Buttyan R. Hormoneregulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992;52:4313-4319